Younger highly myopic patients have a higher risk of being steroid responders

Article

Younger patients with high myopia are at more risk of a postoperative steroid response after uneventful cataract surgery, according to an investigation published in the Journal of Cataract and Refractive Surgery.

Younger patients with high myopia are at more risk of a postoperative steroid response after uneventful cataract surgery, according to an investigation published in the Journal of Cataract and Refractive Surgery.

Dr David F. Chang et al., Los Altos, California, USA, conducted a case-control, retrospective chart review on 1642 patients who underwent uneventful cataract surgery. Patients were administered topical prednisolone acetate 1.0% postoperatively.

Ocular axial length (AL), patient age and intraocular pressure (IOP) were preoperatively recorded, 1-day postoperatively and at least once in the initial postoperative month. During this time the patients received a topical corticosteroid agent.

If the patients experienced an increase in IOP of more than 25% while receiving topical prednisolone, and this reduced by more than 25% once treatment had ceased, then they were considered to be steroid responders. The age and AL of those patients who had a steroid response and those who didn't were compared for analysis.

Out of 1642 patients, 39 were diagnosed as steroid responders. It was concluded that younger age and longer AL were linked with high steroid response risk. The results suggest steroid responders may require more IOP monitoring or topical anti-inflammatory medications.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.